ISHRS S&P M-Cap 400/Barra Growth

Flex Reports FY2026 Earnings: Revenue Beats Expectations, EPS Misses

Flex Plans to Spin Off Cloud and Power Infrastructure Division by Q1 2027

Juniper Therapeutics CEO Martin Rosenthal Sells 9,500 Shares for $5.34 Million

Twilio Named Leader in Gartner CPaaS Magic Quadrant for Fourth Consecutive Year

Flex released FY2026 annual earnings on May 20 Pre-Market EST, actual revenue USD 27.91 B (forecast USD 27.4 B), actual EPS USD 2.33 (forecast USD 2.46)

Third Pillar Fund Increases Twilio Holdings, Directors and CFO Sell Shares

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Abacus Wealth Increases Stake in Sterling Infrastructure as Earnings Beat Expectations

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Fabrinet Reports FY2026 Q3 Results and Issues Cautious Q4 Guidance

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

nVent Announces Stock Repurchase Authorization

Twilio Receives Moderate Buy Rating with $193.65 Target Price, Executives Sell Shares

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Valeo Financial Advisors Acquires $571k of Flex Ltd. Stock in Q4

Twilio Board Member Sells Company Shares

nVent Electric Executive Obtained Stock Options

Guggenheim Upgrades MasTec Rating to Buy

Co-Diagnostics

NewGenIvf

Liminatus Pharma

Agape ATP

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

PicoCELA

Netcapital

Wheeler Real Estate

MIDE

VTWG

MCOW

IVOO

SPMD

As global markets recover post-U.S.-Iran ceasefire, small-cap stocks like S&P MidCap 400 and Russell 2000 gain traction. Investors are eyeing undervalued small caps with insider buying as indicators of potential value. Notable picks include Eastnine, MedCap, and MCAN Mortgage, each showing strong fundamentals and insider confidence despite some financial challenges. Eastnine reported a turnaround in performance, MedCap's revenue growth is promising, and MCAN Mortgage increased dividends, reflecting optimism. The article highlights 170 undervalued global small caps for investors to consider.

Simplywall

Xtrackers S&P MidCap 400 ESG ETF

Vanguard Russell 2000 Growth

VG Mid-Cap Val

NEOS Russell 2000 High Income ETF

ISHRS Russ 2000 Val

iShares Russell 2000

ISHRS Russ 2000 Growth

Pro Rsl 2000 Dvd Grw

VG S&P M-Cap 400 Val

VG S-Cp Grw

Pacer S&P MidCp 400 Qul FCF Arstcrts ETF

Wtree Us M-Cp Fund

Global X Russell 2000 ETF

Vanguard Russell 2000

Vanguard Russell 2000 Value

ProShares Russell 2000 High Income ETF

Direxion Small Cap Bull 3X

SPDR S&P 600 S-Cp Val

SPDR S&P 400 Mid Capgrow

Avantis U.S. Small Cap Value

VG S&P M-Cap 400

SPDR S&P Midcap 400

SPDR Portfolio S&P 400 Mid Cap ETF

Global's Top 3 Undervalued Small Caps With Insider Buying To Consider

DTCR

DigitalOcean Holdings will join the S&P MidCap 400 on April 9, 2026, impacting its capital allocation and trading profile. This move may influence perceptions of growth and risk, particularly in relation to AI-driven growth and high debt levels. Analysts project $1.3 billion in revenue and $182 million in earnings by 2028, but caution exists around churn and pricing pressures. The stock's fair value is estimated at $59.58, indicating a potential downside. Investors are encouraged to consider both optimistic and cautious narratives regarding DigitalOcean's future.

Global X Data Center & Dgtl Infrs ETF

iShares Core S&P Mid Cap

American Century Mid Cap Growth Impact ETF

Digitalocean

ISHRS S&P Glb It

Franklin Exponential Data ETF

Pacer Data & Infrastructure Real Estate ETF

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Proshares Big Data Refiners ETF

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

UTHR

The iShares S&P Mid-Cap 400 Growth ETF (IJK) has seen a significant inflow of approximately $181.1 million, marking a 1.9% increase in outstanding units from 96.65 million to 98.45 million. Key components include Flex Ltd (up 3.1%), United Therapeutics Corp (down 0.3%), and XPO Inc (up 3.8%). IJK's share price is currently at $102.00, within a 52-week range of $71.69 to $108.21. This inflow indicates increased investor demand, impacting the underlying holdings of the ETF.

nasdaq

United Therap

iShares S&P Mid-Cap 400 Growth ETF Experiences Big Inflow

HIMZ

HIMS

CHWY

The iShares S&P Mid-Cap 400 Growth ETF (IJK) experienced unusually high trading volume on Wednesday, with over 1.5 million shares traded compared to a three-month average of 236,000. IJK shares rose by 0.8%. Notable components included Chewy, which surged 13.4% with over 14.6 million shares traded, and Hims & Hers Health, down 1.6% on over 10.4 million shares. Bentley Systems fell by 4.5%.

Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health

Chewy

Wednesday's ETF with Unusual Volume: IJK

SOLS

Solstice Advanced Materials (NasdaqGS:SOLS) has been added to the S&P MidCap 400 during the March 2026 quarterly rebalancing, highlighting its growing significance in the AI supply chain. The stock, currently priced at $72.17, has seen a 46.4% year-to-date return, despite a recent 8.1% decline. This inclusion may influence trading volumes and ownership as index funds adjust their holdings. Analysts have set a target price of $83.83, indicating potential undervaluation. Investors are advised to monitor the company's performance and market positioning closely.

Solstice Advanced Materials

ISHRS S&P M-Cap 400/Barra Val

Solstice Joins S&P MidCap 400 As AI Supply Chain Valuation Story Grows

Arrowhead Pharmaceuticals reported a significant profit surge in Q1 2026, with sales reaching $264.03 million and net income of $30.81 million, a stark contrast to the previous year's $2.5 million in sales. The company was also added to the S&P MidCap 400, indicating a shift in its financial profile. While this move may enhance liquidity and broaden the shareholder base, risks remain tied to clinical trials and partner-dependent revenue. Analysts have varying forecasts for Arrowhead's future revenue, with some projecting a decline, highlighting the uncertainty surrounding its investment narrative.

SPDR S&P Biotech

iShares US Pharma

ArrowHead Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

VG Health

Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?